Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience
Related Experiment Video
Updated: Feb 24, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Rhys D O Jones1, Marie Cooke2, James Hinchliffe3
1IMED Oncology, AstraZeneca Oncology, Cambridge, UK.
Abstract:
In vivo models have been crucial for developing our understanding of key processes associated with human disease and developing novel therapeutics. These in vivo studies are becoming increasingly complex, requiring long-term efficacy data and additional supportive datasets such as pharmacokinetic profiles and analysis of multiple biomarkers of pharmacodynamic response and efficacy. Moreover, a new agent will be investigated in many different models and often in combination with other drugs. Despite advances across the industry integrating and analysing complex datasets, management of in vivo data remains an ongoing challenge across the industry. Here, we describe a project that has successfully delivered a working solution to integrate pharmacokinetic, biomarker and efficacy data, independent of therapy area.
More Related Videos
07:45Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Related Concept Videos
Preclinical Development: Overview
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Product Performance: In Vitro–In Vivo Correlation